Enhanced HD 50K for Angus Available from Zoetis
New advanced genotyping platform developed in partnership with Angus Genetics, Inc.
PARSIPPANY, N.J. (June 22, 2018)—Zoetis has introduced HD 50K™ for Angus, built on a new, enhanced genotyping platform developed in partnership with Angus Genetics, Inc. (AGI), representing the latest innovation in genomic technologies.
Genetic testing results from HD 50K for Angus include parent verification and Genomically-Enhanced Expected Progeny Differences (GE-EPDs). HD 50K for Angus, when combined with Zoetis’ comprehensive portfolio of products, technical services, laboratory excellence and innovation expertise, enables Angus seedstock producers to make selection, breeding and marketing decisions earlier and with confidence.
“Zoetis has enjoyed a long-standing partnership with American Angus Association and we’re very proud to have collaborated closely with Angus Genetics, Inc. to develop this newly enhanced HD 50K for Angus,” said Jason Osterstock, executive director, Global Genetics at Zoetis.
“HD 50K for Angus is the next evolution of genetics services for continued enhancement of the Angus breed,” added Osterstock. “It replaces i50K™ to provide Angus producers with high-density genotyping at the same value.”
“Since 2010, our partnership with Zoetis has brought innovation and leadership in developing genetic tools that help Angus producers realize greater value from more informed breeding and marketing decisions,” said Dan Moser, president of Angus Genetics, Inc. “The HD 50K for Angus genotyping platform is a key part of our overall service model and will be an important and valuable tool for our producers.”
To learn more about HD 50K from Angus, visit Zoetis.com or call 877-233-3362.
HD 50K for Angus is available to American Angus Association members through Angus Genetics, Inc. and may be purchased online through the AAA Login site.
Zoetis (NYSE: ZTS) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetisUS.com.